The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars: How Do They Affect Patient Care & Safety?

Biosimilars: How Do They Affect Patient Care & Safety?

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
hafakot / shutterstock.com

hafakot / shutterstock.com

CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center in Cypress, Calif., where she teaches RN/BSN programs at various facilities, brought the topic of biosimilars to the Annual Meeting and moderated the session.

You Might Also Like
  • The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety
  • Biosimilars to Raise Unique Questions
  • From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective
Explore This Issue
March 2019
Also By This Author
  • COVID-19: Most Individuals with Rheumatic Disease Recover

Ms. Fritz’s interest in the topic stems from her observation that many healthcare providers are uncomfortable prescribing biosimilars. After investigating, she realized many of these perceptions are unfounded.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ms. Fritz then introduced Josephine Garnoc, MSN, RN, CRNI, OCN, director of nursing, Beaumont Hospital, Grosse Pointe, Mich.. Ms. Garnoc agreed with Ms. Fritz, explaining that in her clinical experience, many patients can’t afford the high cost of biologics, but they question the safety and efficacy of biosimilars.1 Healthcare providers are often unwilling or unable to reassure them that biosimilars are a reasonable option.

The U.S. Congress recognized that although only 1–2% of patients in the U.S. are on biologics, biologic use accounted for approximately 38% of healthcare costs.1 To address this, Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which created an abbreviated approval pathway for biologic products that are demonstrated to be “highly similar” to or “interchangeable” with a U.S. Food and Drug Administration (FDA)-approved biological product.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Biosimilars are intended to decrease the cost of biologics and allow more patients access to these products. Several biosimilars have now been approved for use in the U.S., and they share a core name with the reference product. These include: filgrastim-sndz (Zarxio), biosimilar to filgrastim (Neupogen); infliximab-dyyb (Inflectra), biosimilar to infliximab (Remicade); infliximab-abda (Renflexis), biosimilar to infliximab (Remicade); etanercept-szzs (Erelzi), biosimilar to etanercept (Embrel); and adalimumab-atto (Amjevita), biosimilar to adalimumab (Humira).

Biosimilars have a primary amino acid sequence like the originator, and many are glycosylated. The FDA states, “a biosimilar is a biological product that is highly similar to the reference product notwithstanding minor differences in clinically inactive components.” In other words, no clinically meaningful difference between biosimilars and the original biologic can exist.

The FDA approves biosimilars through a stepwise process that evaluates the totality of evidence, biological structure, amino acid sequence, modifications, product stability/quality, binding affinities and mechanism of action. The FDA places an emphasis on comparable pharmacokinetic/pharmacodynamic properties to the reference product. It looks at the totality of this evidence before the biosimilar enters clinical trials.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, adalimumab-atto, etanercept-szzs, filgrastim-sndz, infliximab-abda, infliximab-dyybIssue: March 2019

You Might Also Like:
  • The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety
  • Biosimilars to Raise Unique Questions
  • From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective
  • The Science Behind Biosimilars

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.